Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis

Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients

“…Previous studies have demonstrated significant changes of peripheral blood lymphocyte cell subsets in patients with different malignant lesions and poor prognosis (29)(30)(31)(32). Consequently, we also investigated the T-cell subsets before and after treatment in both groups, which indicated that DC-CIK infusions altered the ratios of T-cell subsets, increasing the T-helper and cytotoxic T lymphocyte (CTL) subsets, while decreasing regulatory T lymphocyte (Treg) subsets, particularly the CD8 + /CD28 -subset.…”

Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients

“…Apoptosis was confirmed as a major mechanism underlying CIK cytotoxicity for the first time. According to a meta-analysis of 27 clinical studies on breast cancer, DC-CIK therapy prolonged 1-year survival, improved the quality-of-life, increased immunity function, and decreased cancer antigen (Wang et al, 2014b). …”

“…Transfused CIK cells died out after the termination of treatment, and therefore it may barely prolong short-term survival. Wang et al (2014b) reported that DC-CIK therapy only prolongs 1-year OS. However, we found the influence of DC-CIK not only on short-term survival but also on long-term survival.…”

Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside

“…DC-CIK cell therapy markedly prolongs survival time enhances immune function and improves the efficacy of the treatment of breast cancer patients. In treated patients, the percentage of T cells (CD3 + , CD4 + and CD4 + CD8 + ), CD16 + monocytes, and CD3 + CD56 + natural killer T cells, the levels of interleukin-2, interleukin-12, tumor necrosis factor-α, interferon-γ, and nucleolar organizer region protein in the peripheral blood of cancer patients was significantly increased (Wang et al, 2014b). DC-CIK was feasible and effective in treating advanced renal cancer (Kim et al, 2014;Su et al, 2010).…”